SAB BIOTHERAPEUTICS, INC. Proceeds from Stock Options Exercised
SAB BIOTHERAPEUTICS, INC. (SABS) reported Proceeds from Stock Options Exercised of $155.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2026-06-30 was $41.88K.
- SAB BIOTHERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2026-03-31 was $113.12K.
- SAB BIOTHERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2024-12-31 was -$3.00, a 100.06% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. proceeds from stock options exercised for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2024 was $20.41K, a 112.99% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2023 was $9.58K, a 87.55% decline from fiscal 2022.
- SAB BIOTHERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2022 was $76.97K, a 1040.31% increase from fiscal 2021.
- SAB BIOTHERAPEUTICS, INC. proceeds from stock options exercised for fiscal 2021 was $6.75K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $155.00K 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | $113.12K 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$3.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$3.00 derived: sum of 2 quarters · filed 2026-03-09 | -$3.00 derived: sum of 3 quarters · filed 2026-03-09 | $20.41K 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $20.41K 10-Q · filed 2025-11-14 | $25.67K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $20.41K 10-Q · filed 2025-08-07 | $25.67K derived: sum of 3 quarters · filed 2025-08-07 | $28.10K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $20.41K 10-Q · filed 2025-05-09 | $25.67K derived: sum of 2 quarters · filed 2025-05-09 | $28.10K derived: sum of 3 quarters · filed 2025-05-09 | $28.10K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $5.26K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $7.69K derived: sum of 2 quarters · filed 2025-03-31 | $7.69K derived: sum of 3 quarters · filed 2025-03-31 | $9.58K 10-K · filed 2025-03-31 |
| 2023-09-30 | $2.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.43K derived: sum of 2 quarters · filed 2024-11-06 | $4.32K 10-Q · filed 2024-11-06 | $4.32K derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.89K 10-Q · filed 2024-08-08 | $1.89K derived: sum of 3 quarters · filed 2024-08-08 | $1.89K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.89K 10-Q · filed 2024-05-20 | $1.89K derived: sum of 2 quarters · filed 2024-05-20 | $1.89K derived: sum of 3 quarters · filed 2024-05-20 | $71.03K derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $69.14K derived: sum of 3 quarters · filed 2024-03-29 | $76.97K 10-K · filed 2024-03-29 |
| 2022-09-30 | $1.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $69.14K derived: sum of 2 quarters · filed 2023-11-13 | $76.97K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $69.14K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $76.97K 10-Q · filed 2023-08-21 | ||
| 2022-03-31 | $7.83K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $6.75K 10-K/A · filed 2023-04-28 | |||
| 2020-12-31 | $0.00 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |